Toward clinical development of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC).

被引：4
|
作者：
Verheijden, Gijs
Beusker, Patrick
Ubink, Ruud
van der Lee, Miranda
Groothuis, Patrick
Goedings, Peter J.
Egging, David
Mattaar, Ellen
Timmers, Macro
Dokter, Wim
机构：
[1] Synthon Biopharmaceut BV, Nijmegen, Netherlands
[2] Synthon BV, Nijmegen, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.626
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
626
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.
    Hamilton, Erika Paige
    Barve, Minal A.
    Bardia, Aditya
    Beeram, Muralidhar
    Bendell, Johanna C.
    Mosher, Rebecca
    Hailman, Eric
    Bergstrom, Donald Alan
    Burris, Howard A.
    Soliman, Hatem Hussein
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Assessment of a HER-2 scoring system and its correlation of HER2-targeting antibody-drug conjugate therapy in urothelial carcinoma.
    Lei, Huizi
    Ling, Yun
    Yuan, Pei
    Guo, Jun
    Sheng, Xinan
    Zhou, Ai-Ping
    Ying, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] CLINICAL PHARMACOLOGY OF T-DM1: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) IN DEVELOPMENT FOR THE TREATMENT OF HER2-POSITIVE (HER2+) CANCER
    Girish, S.
    Gupta, M.
    Wang, B.
    Lu, D.
    Krop, I.
    Vogel, C.
    Burris, H.
    Yi, J.
    Saad, O.
    Tong, B.
    Klencke, B.
    Agresta, S.
    Chu, W.
    Joshi, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S12 - S12
  • [24] SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer
    Aftimos, P. G.
    van Herpen, C. M.
    Mommers, E. C.
    Koper, N. P.
    Goedings, P.
    Oesterholt, M.
    Awada, A.
    Desar, I. M.
    Lim, J.
    Dean, E.
    Rolfo, C.
    Macpherson, I.
    Banerji, U.
    CANCER RESEARCH, 2017, 77
  • [25] Developing a novel doppel-targeting antibody-drug conjugate (ADC) for solid cancer
    Lee, Ha Kyeong
    Kim, Byoungmo
    Kweon, Seho
    Choi, Jeong Uk
    Kim, Sang Yoon
    Byun, Youngro
    CANCER RESEARCH, 2023, 83 (07)
  • [26] A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
    Iwata, Tomomi Nakayama
    Ishii, Chiaki
    Ishida, Saori
    Ogitani, Yusuke
    Wada, Teiji
    Agatsuma, Toshinori
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (07) : 1494 - 1503
  • [27] Development and validation of pharmacokinetics assays for a novel HER2-targeting antibody-drug conjugate (SHR-A1201): Application to its dose-escalation pharmacokinetic study
    Li, Xianjing
    Wang, Yiya
    Hu, Wenhui
    Song, Qinxin
    Ding, Li
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2024, 240
  • [28] ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
    Li, John Y.
    Perry, Samuel R.
    Muniz-Medina, Vanessa
    Wang, Xinzhong
    Wetzel, Leslie K.
    Rebelatto, Marlon C.
    Hinrichs, Mary Jane Masson
    Bezabeh, Binyam Z.
    Fleming, Ryan L.
    Dimasi, Nazzareno
    Feng, Hui
    Toader, Dorin
    Yuan, Andy Q.
    Xu, Lan
    Lin, Jia
    Gao, Changshou
    Wu, Herren
    Dixit, Rakesh
    Osbourn, Jane K.
    Coats, Steven R.
    CANCER CELL, 2016, 29 (01) : 117 - 129
  • [29] Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers
    Li, Yongpeng
    Li, Lin
    Fu, Haoyu
    Yao, Qing
    Wang, Lei
    Lou, Liguang
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (01): : 161 - +
  • [30] Preclinical development of a novel antibody-drug conjugate targeting "cold" tumors
    Kaplan, Angelo
    Attanasio, Nickolas
    Do, To Uyen T.
    Swaminathan, Sudha
    Bisht, Arnima
    Lou, San Lin
    Allen, Jason
    Boyd, Robert
    Ackroyd, James E.
    Feldman, Gleb
    Rohlff, Christian
    Dusek, Rachel L.
    CANCER RESEARCH, 2018, 78 (13)
12345